Improvements in Skin Clearance and Patient-Reported Outcomes were Greater with Guselkumab Compared with Ustekinumab Among Patients with Persistent Mild Psoriasis After 16-Weeks of Treatment with Ustekinumab
- S Khattri (Autor*in)
- E Errichetti (Autor*in)
- Wolf, P. (Autor*in)
- K Shams (Autor*in)
- P Gorecki (Autor*in)
- YW Yang (Autor*in)
- M Miller (Autor*in)
- JZ Jiang (Autor*in)
- CL Han (Autor*in)
- B Kirby (Autor*in)
Aktivität: Vortrag oder Poster › Poster